FTC Will Push To Block $3.1B CSL-Talecris Merger

Law360, New York (May 26, 2009, 12:00 AM EDT) -- Federal Trade Commission staff members oppose blood plasma-derived therapeutics company CSL Ltd.'s proposed $3.1 billion acquisition of rival Talecris Biotherapeutics and have asked the agency to block the deal, CSL has announced.

Commissioners told CSL managing director Brian McNamee in a meeting Friday that FTC staff recommended that the agency take action in federal court to stop the merger, the company revealed Monday.

CSL expects a vote and a decision on the merger from the commission by Thursday, it said.

An FTC spokesman would not comment...
To view the full article, register now.